A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors

Basit Öğe Kaydı
dc.authoridŞahin, Ali/0000-0001-7231-2394
dc.authorwosidŞahin, Ali/GOG-8747-2022
dc.contributor.authorInanc, Guezide Nevsun
dc.contributor.authorTerzioglu, Mustafa Ender
dc.contributor.authorKarabulut, Yusuf
dc.contributor.authorYilmaz, Zevcet
dc.contributor.authorTarhan, Emine Figen
dc.contributor.authorEnecik, Mehmet Emin
dc.contributor.authorSahin, Ali
dc.date.accessioned2024-08-04T20:10:21Z
dc.date.available2024-08-04T20:10:21Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground/aim: To describe the disease activity and retention rate in rheumatoid arthritis (RA) patients with inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or tumor necrosis factor inhibitors (TNFis) who were prescribed tocilizumab (TCZ) as first-line or second-line biologic treatment in real-world setting.Materials and methods: Data gathered from patients' files was used in a multicenter and retrospective context. Retention rates and the Disease Activity Score in 28 joints with CRP (DAS28-CRP) were evaluated at time points. The relationship of drug efficacy with factors such as smoking, obesity, and previous use of TNFis was also examined.Results: One hundred and twenty-four patients with a median (IQR) RA duration of 3.7 (7.4) years were included. Mean (SD) age was 52.9 (12.9) and 75% of the patients were female. TCZ retention rates in the 6th and 12th months were 94.1% and 86.6%, respectively. In all patients, DAS28-CRP level decreased significantly from baseline to Months 3 and 6. There was an increase in patients with remission and/or low disease activity and a decrease in patients with high disease activity at Month 3 and Month 6 (p < 0.001 for both). Disease activity was similar between subgroups based on body mass index, smoking status, and previous use of TNFis at any time point. Regres-sion analysis showed that absence of concomitant corticosteroid treatment independently was associated with remission/LDA achieve-ment at Month 6 [OR = 0.31, 95% CI (0.14- 0.72), p = 0.006], and Month 12 [OR = 0.35, 95% CI (0.13-0.94), p = 0.037]. Overall, 25 mild adverse events were reported.Conclusion: TCZ was found to be effective and safe in RA patients with IR to csDMARDs and/or TNFis. The drug retention rate was considered satisfactory with more than half of the patients continuing TCZ treatment at Month 12.en_US
dc.description.sponsorshipRoche Mustahzarlari San AS., Turkeyen_US
dc.description.sponsorshipThe study was funded by Roche Mustahzarlari San AS., Turkey in accordance with Good Publication Practice (GPP3) guidelines. All authors contributed to the conduction and writing of this study and have approved the final version.& nbsp;en_US
dc.identifier.doi10.55730/1300-0144.5636
dc.identifier.endpage743en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue3en_US
dc.identifier.pmid37476902en_US
dc.identifier.scopus2-s2.0-85163656306en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage731en_US
dc.identifier.trdizinid1191045en_US
dc.identifier.urihttps://doi.org/10.55730/1300-0144.5636
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1191045
dc.identifier.urihttps://hdl.handle.net/11616/92725
dc.identifier.volume53en_US
dc.identifier.wosWOS:001022334700013en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRheumatoid arthritisen_US
dc.subjectanti-interleukin-6en_US
dc.subjecttocilizumaben_US
dc.titleA national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu